Clinical operations teams are using AI simulations to spot enrollment swings and operational threats early, giving them a sharper edge as trial complexity climbs.
Acquirers are snapping up private biotech startups at a pace not seen before in 2026. Public biotech stocks have lost momentum, and investor nerves are showing. Private M&A now sets the tone for the sector.
OpenCGChromatin, a new open-source tool, lets scientists simulate chromatin folding and molecular interactions at scales that were previously out of reach. The software promises new ways to study DNA packaging and genome structure.
A whole exome sequencing workflow now lets researchers analyze both coding and non-coding variants tied to drug response and safety, pushing past the limits of targeted panels.
GenoMethods explains biotechnology from method to medicine to market, connecting scientific evidence, clinical development, companies and the technologies shaping future health.
